For patients with severe CRSwNP and concomitant eosinophilic otitis media, dupilumab treatment may provide meaningful benefits over a 12-month period.

Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study.

SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for further treatments, the WAYPOINT trial showed. The monoclonal ...

CRSwNP is a chronic inflammatory condition characterized by nasal polyps, persistent nasal symptoms and impaired smell, and ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates. Advancements in biologic therapies are ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial investigators, conducted two Phase III clinical trials to evaluate depemokimab, ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Most people with chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But some people with this ...

Please provide your email address to receive an email when new articles are posted on . The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...